|
| General Information |
| Business: |
We are a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel products to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds and connective tissue disorders. Our innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency, or the EMA, in December 2012 for removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. NexoBrid, which is based on our patented proteolytic enzyme technology, represents a new paradigm in burn care management, and our clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier upon patient admission, without harming viable tissues. We launched NexoBrid in December 2013 in the European Union through our wholly-owned German subsidiary, targeting a focused audience of burn specialists treating patients in burn centers and hospital burn units. We also plan to initiate a Phase 3 pivotal study in the United States in the first half of 2014 to support a Biologics License Application, or BLA, submission to the United States Food and Drug Administration, or FDA. We manufacture NexoBrid in our state-of-the-art, EMA-certified, cGMP-compliant, sterile pharmaceutical products manufacturing facility at our headquarters in Yavne, Israel. |
|
| Industry: |
MEDICINAL CHEMICALS & BOTANICAL PRODUCTS |
|
| Employees: |
43 |
Founded: |
2000 |
|
| Contact Information |
| Address: |
42 Hayarkon Street, Yavne 8122745, IL |
|
|
|
|
|
|
|
| Financial Information |
| |
| Revenues: |
$ 0.0 mil (last 12 months) |
|
| Net Income: |
$ -15.4 mil (last 12 months) |
|
| IPO Profile |
| Symbol: |
MDWD |
| Shares (millions): |
5.0 |
| Price Range: |
$14.00 - $14.00 |
| Est.$ Volume |
$ 70.0 mil |
| Manager / Joint Managers |
Credit Suisse/ Jefferies/ BMO Capital Markets |
| Co Managers |
Oppenheimer |
| Expected to Trade |
3/20/2014 |
| Status |
Priced |
| SCOOP RATING |
Available only to Subscribers |
| RATING CHANGE |
Available only to Subscribers |
|
|
|
|
